What it is
CJC-1295 with DAC is a long-acting GHRH analog studied for longer GH and IGF-1 exposure from one or two injections per week.
Evidence boundary
Investigational / limited human evidence.
Trial evidence
- PMID 42578445 — Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
- PMID 42160466 — Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
- PMID 42123471 — Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
Preparation and measurement
Reconstitution: 5 mg vial + 2 mL BAC = 2.5 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–2 (titration) | 300 mcg | 12 U (0.12 mL) | 1–2× weekly | 300–600 mcg/week |
| Weeks 3–4 | 500 mcg | 20 U (0.2 mL) | 1–2× weekly | 0.5–1 mg/week |
| Weeks 5–6 | 750 mcg | 30 U (0.3 mL) | 1–2× weekly | 0.75–1.5 mg/week |
| Weeks 7–12 (target) | 1 mg | 40 U (0.4 mL) | 1–2× weekly | 1–2 mg/week |
Weeks 1–2 (titration)
- Dose
- 300 mcg
- Draw / measure
- 12 U (0.12 mL)
- Frequency
- 1–2× weekly
- Weekly total
- 300–600 mcg/week
Weeks 3–4
- Dose
- 500 mcg
- Draw / measure
- 20 U (0.2 mL)
- Frequency
- 1–2× weekly
- Weekly total
- 0.5–1 mg/week
Weeks 5–6
- Dose
- 750 mcg
- Draw / measure
- 30 U (0.3 mL)
- Frequency
- 1–2× weekly
- Weekly total
- 0.75–1.5 mg/week
Weeks 7–12 (target)
- Dose
- 1 mg
- Draw / measure
- 40 U (0.4 mL)
- Frequency
- 1–2× weekly
- Weekly total
- 1–2 mg/week
Weekly totals apply only during the active phase.
Titration rules
-
Titration schedule (1–2× weekly):
-
Weeks 1–2 (titration): 300 mcg per dose.
-
Weeks 3–4: 500 mcg per dose.
-
Weeks 5–6: 750 mcg per dose.
-
Weeks 7–12 (target): 1.0 mg per dose, 1–2× weekly.
-
Timing: Day-of-week is flexible because of the long half-life. A common protocol dose Sunday/Wednesday or Monday/Thursday for the twice-weekly schedule.
-
GH and IGF-1 response
-
Fluid retention
-
Tingling or carpal-tunnel-like symptoms
-
Headache
Practical rules
- Dose on a consistent day pattern only if a clinician has a reason.
- Monitor glucose periodically.
- Keep sleep and training steady.
- Rotate sites.
Related protocols
CJC-1295 (No DAC) Peptide Protocol & DosingIpamorelin Peptide Protocol & DosingGHRP-2 Peptide Protocol & DosingSermorelin Peptide Protocol & DosingTesamorelin Peptide Protocol & Dosing Supply & lot verification
Availability and batch-linked COA records for CJC-1295 (DAC) Peptide Protocol & Dosing are kept with the current product listing.
View availability & COA → Verification notes